EUVIMEDEUVIMED entdecken
Crossref

Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy

Ahmet Kucukarda, Burcu Gulbagci, Elif Yuce

Oncology in Clinical Practice · 2025

DOI: 10.5603/ocp.101103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology in Clinical Practice, 2025. Verfasst von Ahmet Kucukarda und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kucukarda, A., Gulbagci, B., & Yuce, E. (2025). Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy. Oncology in Clinical Practice. https://doi.org/10.5603/ocp.101103

Vancouver

Kucukarda A, Gulbagci B, Yuce E. Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy. Oncology in Clinical Practice. 2025. doi:10.5603/ocp.101103

BibTeX
@article{Kucukarda2025,
  author = {Kucukarda, Ahmet and Gulbagci, Burcu and Yuce, Elif},
  title = {Gustave Roussy immune score is an independent prognostic factor for treatment response and survival in advanced non-small cell lung cancer treated with nivolumab at second-line therapy},
  journal = {Oncology in Clinical Practice},
  year = {2025},
  doi = {10.5603/ocp.101103}
}
Kostenlos starten →